Vicore Pharma: Unlocking the Potential of ATRAGs at Upcoming Investor Conferences

Vicore Pharma Holding AB (publ), a clinical-stage biopharmaceutical company, is set to present at several upcoming investor conferences, providing an opportunity for investors to learn more about its innovative drug candidates, particularly its lead program, buloxibutid (C21). The company's strategic approach to investor relations, which includes participating in multiple conferences, contributes significantly to its overall investment thesis and potential for growth.



Vicore Pharma is scheduled to participate in the following investor conferences:

1. Guggenheim 6th Annual Biotechnology Conference
* Location: New York, NY
* Fireside Chat Date and Time: February 7 at 2:30 PM ET/8:30 PM CET
* Webcast Registration:
2. Oppenheimer 34th Annual Healthcare Life Sciences Conference
* Presentation Date and Time: February 13 at 10:40 AM ET/4:40 PM CET
* Webcast Registration:
3. 28th Annual Carnegie Nordic Healthcare Seminar
* Location: Stockholm, Sweden
* Presentation Date and Time: March 12 at 7:00 AM ET/1:00 PM CET
* Participants: Ahmed Mousa, CEO; Hans Jeppsson, CFO

Vicore Pharma's presentations at these conferences will provide investors with valuable insights into the company's clinical development progress, the potential of buloxibutid, and its overall strategy in the respiratory and fibrotic diseases space. The company may discuss updates on the ongoing Phase 2b ASPIRE trial, the mechanism of action of buloxibutid, biomarker data, safety and tolerability, regulatory pathway, competitive landscape, business development, and more.

By attending these presentations, investors can gain a better understanding of Vicore's clinical development progress, the potential of buloxibutid, and the company's overall strategy in the respiratory and fibrotic diseases space. This increased visibility and engagement with investors can help Vicore raise awareness about its innovative drug candidates, foster networking and partnership opportunities, support fundraising efforts, build reputation and credibility, and provide valuable feedback and market intelligence.

In conclusion, Vicore Pharma's participation in upcoming investor conferences is an excellent opportunity for investors to learn more about the company's innovative drug candidates, particularly its lead program, buloxibutid. By attending these presentations, investors can gain valuable insights into the company's clinical development progress, the potential of buloxibutid, and its overall strategy in the respiratory and fibrotic diseases space. This increased visibility and engagement with investors can help Vicore raise awareness, foster partnerships, support fundraising, build reputation, and gather valuable feedback.